FDA Brief

Company record

Scope Health Inc

1 FDA warning letter since 2023 and 1 recall in the last 12 months.

Get an email the day FDA posts anything new about Scope Health Inc.

Warning letters

  1. Scope Health Inc

    FDA says Scope Health sold unapproved OTC eye drugs online and misbranded several products.

    High risk

Recalls

ReportedClassFirmProduct and reason
May 6 Class II SCOPE HEALTH
Drug
Optase Dry Eye Intense Drops (Glycerin 0.2%), packaged in 0.33 fl oz, Sterile, Manufactured for Scope Health Inc., 79 Madison Ave., 8th Floor, New York, NY 10016, USA, NDC 72972-002-01.
Lack of Assurance of Sterility